

The Lobular Breast Cancer Alliance (LBCA)

ADVANCE
RESEARCH

BUILD
PARTNERSHIPS

EDUCATE
ABOUT ILC

The **Lobular Breast Cancer Alliance (LBCA)** is a patient-driven advocacy network working with a scientific advisory board of breast cancer researchers and clinicians.

Our goal is to promote research that advances prevention, diagnosis, treatment and follow-up care for patients with lobular breast cancer (ILC).

Please join us!

Go to

www.lobularbreastcancer.org

to learn more, sign up
and donate



Invasive Lobular Breast Cancer (ILC)
a distinct type of breast cancer

- ILC is the **second most common histological subtype of breast cancer** with 39,000 patients diagnosed each year and approximately 450,000 patients living with the disease in the US.
- ILC is a **biologically distinct breast cancer** with its own unique subtypes and variants, different clinical presentation and a tendency to metastasize to unique locations. A better understanding of ILC's unique biology and behaviors could open doors to effective targeted therapies.
- Lobular breast cancer is **harder to detect** in screening, advanced imaging and self-exams leading to later staging at diagnosis
- ILC may respond differently to standard of care chemotherapy and endocrine therapies, requiring more clinical trials to refine treatments for patients.
- Lobular breast tumors frequently recur** many years after initial diagnosis. While ILC is often associated with good initial prognosis, recent analysis suggests that longterm outcomes may be worse.

X More Research NEEDED